(0.34%) 5 117.12 points
(0.33%) 38 366 points
(0.38%) 15 989 points
(-0.97%) $83.04
(5.56%) $2.03
(0.34%) $2 355.20
(0.48%) $27.67
(4.06%) $959.50
(-0.26%) $0.932
(-0.43%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
@ $1.840
発行日: 15 2月 2024 @ 01:29
リターン: -6.25%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -1.60 %
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
本日の出来高 | 66 227.00 |
平均出来高 | 289 862 |
時価総額 | 33.18M |
EPS | $-0.530 ( 2024-04-04 ) |
次の収益日 | ( $-2.03 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.200 |
ATR14 | $0.00900 (0.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Jin David | Buy | 2 352 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 22 705 545 | Sell: 91 742 |
ボリューム 相関
Fortress Biotech Inc 相関 - 通貨/商品
Fortress Biotech Inc 財務諸表
Annual | 2023 |
収益: | $84.51M |
総利益: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
収益: | $84.51M |
総利益: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
収益: | $75.74M |
総利益: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
収益: | $63.13M |
総利益: | $31.05M (49.18 %) |
EPS: | $-0.800 |
Financial Reports:
No articles found.
Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。